-

Red Nucleus Named to the 2026 MM+M Agency 100

Recognition Highlights Red Nucleus’ Leadership in Life Sciences Commercialization

YARDLEY, Penn.--(BUSINESS WIRE)--Red Nucleus, a leading, global provider of strategic services and solutions across the life sciences product lifecycle, today announced its inclusion in the 2026 MM+M Agency 100, the annual ranking of the most influential healthcare marketing and communications agencies in North America. Published by MM+M (Medical Marketing + Media), the Agency 100 recognizes organizations that are shaping the future of healthcare communications through innovation, scientific expertise, strategic insight, and measurable client impact.

“We are honored to be recognized by MM+M as part of the Agency 100,” said Mike Menta, Chief Executive Officer of Red Nucleus. “This recognition reflects the extraordinary talent, passion, and commitment of our global team. As the healthcare landscape continues to evolve, we remain focused on helping our clients navigate complexity, accelerate commercialization, and ultimately improve outcomes for patients around the world.”

With operations across North America, Europe, Asia, and Latin America, Red Nucleus partners with life sciences organizations at every stage of the commercialization journey. The company supports many of the industry's leading pharmaceutical and biotechnology organizations through integrated capabilities spanning Medical Affairs, Value & Evidence, Commercial, Research and Development, and Learning & Development.

The recognition underscores Red Nucleus’ continued growth and leadership in supporting life sciences organizations across the commercialization journey.

To read Red Nucleus’ full profile in the 2026 MM+M Agency 100, visit:

HTTPS://WWW.MMM-ONLINE.COM/COMPANYDETAIL/RED-NUCLEUS-AGENCY-100-2026/

About Red Nucleus

Red Nucleus is a global strategic partner trusted to deliver transformative solutions across the entire life sciences product lifecycle. By connecting its full suite of products and services, Red Nucleus serves clients through transformational change to accelerate success. With expertise spanning Medical Affairs, Value & Evidence, Commercial, Research and Development, and Learning & Development, Red Nucleus helps life sciences organizations bring therapies to market and maximize their impact on patients worldwide. Guided by its vision of improving the health of patients around the world by solving healthcare’s most pressing challenges, Red Nucleus advances knowledge to improve lives.

Contacts

Media Inquiries
Mary Kilmartin
mary.kilmartin@edelmansmithfield.com

Red Nucleus


Release Versions

Contacts

Media Inquiries
Mary Kilmartin
mary.kilmartin@edelmansmithfield.com

More News From Red Nucleus

Red Nucleus to Acquire Bridge Medical Consulting, Expanding Health Economics and Outcomes Research Capabilities

YARDLEY, Pa.--(BUSINESS WIRE)--Red Nucleus, a leading provider of strategic services across research and development, medical affairs, market access, commercial, and learning & development, today announced that it has acquired Bridge Medical Consulting, a specialized health economics and outcomes research (HEOR) consultancy. The acquisition represents a key step in Red Nucleus’s strategy, strengthening its ability to help biopharmaceutical companies demonstrate the clinical and economic val...

Red Nucleus Announces Acquisition of COEUS

YARDLEY, Pa.--(BUSINESS WIRE)--Red Nucleus, a leading provider of strategic services across research and development, medical affairs, market access, commercial solutions, and learning and development, today announced that it has acquired COEUS, a multi-specialty, commercially aligned consultancy offering a comprehensive suite of informed solutions for successful engagement with organized customers, providers, and patients. Established in 2009 and recognized as a leader in market access consult...

Red Nucleus Announces Majority Investment from THL Partners

YARDLEY, Pa.--(BUSINESS WIRE)--Red Nucleus ( “the Company”), a leading provider of strategic services across research and development, medical affairs, market access, and learning and development, today announced that it has received a majority investment from THL Partners (“THL”), a premier private equity firm investing in middle market growth companies. The strategic partnership will help broaden the Company’s suite of commercialization services for its global customer base. The Company furth...
Back to Newsroom